The General Director of Biosim, Regina Múzquiz, has participated in the Congress on biosimilar medicines organized by the association "Medicines for Europe", held in London at the end of March. The meeting focused on the mechanisms and strategies to promote access to new biological therapies, especially in oncology, and how biosimilar medicines present themselves as a clear opportunity to improve access to these medicines, compatible with promoting sustainability. of health systems.
Medicines for Europe represents the European pharmaceutical companies that supply the majority of medicines across Europe, and is the voice of the value-added industry in the area of generics and biosimilars.
During the meeting, Biosim has shared with other associations and companies at the European level its experiences and strategies in disseminating the value of biosimilar drugs to expand and improve therapeutic options for patients, to promote care innovation, and to improve the efficiency and sustainability of the Spanish health system.
